ANGIOTENSIN CONVERTING ENZYME-INHIBITORS

被引：31

作者：

BAUER, JH

机构：

[1] Hypertension Section, Nephrology Division, Department of Medicine, University of Missouri

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1990年 / 3卷 / 04期

关键词：

Angiotensin converting enzyme inhibitors; Captopril; Efficacy; Enalapril; Lisinopril; Renal function; Safety;

D O I：

10.1093/ajh/3.4.331

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension. © 1990 by the American Journal of Hypertension, Ltd.

引用

页码：331 / 337

页数：7

共 133 条

[1]

Fagard R., Amery A., Lijnen P., Reybronck T., Haemodynamic effects of captopril in hypertensive patients: comparison with saralasin, Clin Sci, 57, pp. 131s-134s, (1979)

[2]

de Bruyn J.H.B., Man in't Veld A.J., Wenting G.J., Et al., Haemodynamic profile of captopril treatment in various forms of hypertension, Eur J Clin Pharmacol, 20, pp. 163-168, (1981)

[3]

Fagard R., Bulpitt C., Lijnen P., Amery A., Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients, Circulation, 65, pp. 33-39, (1982)

[4]

Lund-Johansen P., Omvik P., Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension, J Hypertens, 2, pp. 49-56, (1984)

[5]

Fouad F.M., Tarazi R.C., Bravo E.L., Textor S.C., Hemodynamic and antihypertensive effects of the new oral angiotensin-converting enzyme inhibitor MK421 (Enalapril), Hypertension, 6, pp. 167-174, (1984)

[6]

Gavras H., Brunner H.R., Laragh J.H., Et al., An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N Engl J Med, 291, pp. 817-821, (1974)

[7]

Case D.B., Wallace J.M., Keim H.J., Et al., Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme, N Engl J Med, 296, pp. 641-646, (1977)

[8]

Johnston C.I., Millar J.A., McGrath B.P., Matthews P.G., Long-term effects of captopril (SQ 14225) on blood pressure and hormonal levels in essential hypertension, Lancet, 2, pp. 493-496, (1979)

[9]

Atlas S.A., Case D.B., Sealey J.E., Et al., Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis, Hypertension, 1, pp. 274-280, (1979)

[10]

Textor S.C., Brunner H.R., Gavras H., Converting enzyme inhibition during chronic angiotensin II infusion in rats, Hypertension, 3, pp. 269-275, (1981)

← 1 2 3 4 5 6 7 8 9 10 →